Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp. lactis + lacticaseibacillus rhamnosus
- Development stage
- Phase 3
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a **combination of two probiotic bacterial strains**: Bifidobacterium animalis subsp. lactis (typically the BB-12 strain) and Lacticaseibacillus rhamnosus (commonly the GG strain, historically known as Lactobacillus rhamnosus GG). Both components are live biotherapeutic probiotic organisms. The combination is orally administered and is intended to support **gastrointestinal health, modulation of the immune system, and restoration of a healthy intestinal microbiota**. Clinical studies have explored its use for preventing or treating malabsorption and weight gain issues in premature infants, reducing gastrointestinal infections, preventing antibiotic-associated diarrhea, and as adjunctive therapy to support immune response in older adults[1][2][3]. The key mechanisms are competitive exclusion of pathogenic microbes, enhancement of the gut barrier, modulation of local and systemic immune function, promotion of beneficial gut colonization, and production of metabolic substances such as short-chain fatty acids[1][2].
- Brand names
- Probio-Tec BG-VCap-6.5
- Other names
- bifidobacterium animalis subsp. lactis + lactobacillus rhamnosusbifidobacterium animalis subsp. lactis BB-12 + lacticaseibacillus rhamnosus GGBB-12 + LGG
02
Targets
TLR (Toll-like receptors)
Beyond the preview
Go deeper on bifidobacterium animalis subsp. lactis + lacticaseibacillus rhamnosus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp. lactis + lacticaseibacillus rhamnosus.